NovoCure Director Ashley Cordova Departs Board

NovoCure Ltd (NVCR) disclosed that director Ashley Cordova has departed its board of directors, according to an 8-K filed with the SEC on June 5, 2026.

The filing, submitted under Item 5.02, identifies Cordova as an outgoing director with no successor named in the document. Item 5.07 confirms that the company also held its annual meeting of security holders on the same date, during which matters were submitted to a shareholder vote. Item 9.01 includes exhibits supporting the disclosures.

NovoCure, a commercial-stage oncology company that markets Tumor Treating Fields therapy for glioblastoma and other solid tumors, now operates with one fewer board member. Public companies listed on Nasdaq must maintain a board that satisfies independent director and committee-composition rules under exchange listing standards and SEC regulations.

The departure reduces the total number of directors by one until any replacement is elected.

The change takes effect immediately upon the filing date of June 5, 2026. Under SEC rules, the Form 8-K itself satisfies the company's initial disclosure obligation. Any subsequent election of a new director will require an additional Form 8-K within four business days of that appointment.

The company must also ensure continued compliance with Nasdaq's majority-independent board requirement and audit, compensation, and nominating committee standards, which may necessitate filling the vacancy within the time frames set by those rules or risk delisting procedures.

Downstream, the departure obliges NovoCure to evaluate board committee assignments and may accelerate the timetable for nominating a replacement ahead of its next annual shareholder meeting. If the board falls below the minimum independent-director threshold even temporarily, it must notify Nasdaq and submit a plan to regain compliance.

The filing also updates the company's official governance record, which investors and proxy advisory firms consult when assessing board quality and independence for upcoming votes.

This marks the latest board-level change for NovoCure following a series of prior director transitions disclosed in separate 8-K filings over the past 24 months. The company last reported annual-meeting voting results in its 2025 proxy statement.